[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646933":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":62,"collaborators":66,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":19,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":19,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":19,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Postoperative Radiotherapy","EXPERIMENTAL","Patients undergo moderately hypofractionated IMRT after radical hysterectomy",[13],"Radiation: Postoperative Radiotherapy",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","Postoperative moderately hypofractionated IMRT (2.5Gy per fraction, 17 fractions, once a day)",[9],null,[21],{"name":22,"affiliation":5,"role":23},"MAN NI HUANG, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","8610-87788495","huangmanni@csco.ac.cn",[30,47],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Cancer Hospital, Chinese Academy of Medical Sciences","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45,46],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},{"name":22,"role":23,"phone":19,"phoneExt":19,"email":19},{"facility":48,"status":32,"city":49,"state":50,"zip":51,"country":36,"countryCode":37,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Lang Fang Campus of Cancer Hospital, Chinese Academy of Medical Sciences","Langfang","Hebei","065001",{"type":39,"coordinates":53},[54,55],116.71471,39.52079,{"lat":55,"lon":54},[58,61],{"name":59,"role":26,"phone":60,"phoneExt":19,"email":19},"JU SHENG AN, MD","0316-5918495",{"name":59,"role":23,"phone":19,"phoneExt":19,"email":19},{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Manni Huang","Principal Investigator",[67],{"name":5,"class":6},"100646933","adjuvant-moderately-hypofractionated-intensity-modulated-radiotherapy-for-cervical-cancer-100646933",false,"NCT07684508","Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer","Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Postoperative Cervical Cancer (AMICA-CC) : a Prospective, Multicenter, Phase II Trial","Inclusion Criteria:\n\n* ECOG performance status 0 or 1;\n* Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;\n* Status post radical hysterectomy with pelvic lymph node dissection with or without para-aortic lymph node dissection, and postoperative radiotherapy initiated within 3 months;\n* For squamous cell carcinoma: meeting Sedlis criteria; for adenocarcinoma and adenosquamous carcinoma: meeting the \"four-factor model\";\n* Bone marrow function: white blood cell (WBC) count ≥3.0×10⁹\u002FL, neutrophil count (NEUT) ≥1.5×10⁹\u002FL, platelet count (PLT) ≥80×10⁹\u002FL, hemoglobin (Hb) ≥90 g\u002FL; renal function: normal or serum creatinine (SCr) ≤1.5×upper limit of normal (ULN) or creatinine clearance ≥50 ml\u002Fmin; hepatic function: total bilirubin (TBIL) ≤1.5×ULN, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5×ULN;\n* Voluntarily signed the informed consent form prior to study enrollment.\n\nExclusion Criteria:\n\n* History of active malignant tumor within 3 years prior to initial treatment（except for the cervical cancer）and any locally curable tumors treated with radical therapy;\n* Any high-risk factor confirmed by postoperative pathology: positive lymph node metastasis, positive parametrial invasion, or positive resection margin;\n* History of neoadjuvant therapy prior to enrollment;\n* Local recurrence or distant metastasis prior to enrollment;\n* Postoperative intestinal obstruction or intestinal adhesion;\n* Severe cardiac, cerebral, hepatic, or renal disorders;\n* Long-term immunocompromised state;\n* Pregnant or lactating females;\n* Premature discontinuation of treatment for any reason;\n* Poor compliance, unwillingness to participate, or inability to cooperate with follow-up;\n* Any other conditions deemed unsuitable for this trial by the investigator.","FEMALE","18 Years","75 Years",{"count":79,"type":80},154,"ESTIMATED","INTERVENTIONAL",[83],"NA","To investigate the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in the treatment of postoperative cervical cancer",[86,87,88],"Hypofractionated Radiotherapy","Intensity-modulated Radiotherapy","Cervical Cancers","2026-08-03",{"date":91,"type":92},"2026-08-05","ACTUAL",{"date":94,"type":92},"2026-07-10",{"date":96,"type":80},"2030-12-30",{"name":64,"class":6},2]